门冬氨酸阿奇霉素治疗小儿支原体肺炎的疗效观察

Observation on the Clinical Effects of Azithromycin Aspartate on the Treatment of Mycoplasma Pneumonia in Children

目的:探讨阿奇霉素治疗小儿支原体肺炎的疗效及安全性。方法:采用随机对照方法将84例支原体肺炎患儿随机分成治疗组和对照组各42例。治疗组给予门冬氨酸阿奇霉素10mg/(kg.d)静脉滴注,1次/d,疗程5～7d;对照组给予红霉素20mg/(kg.d)静脉滴注,2次/d,疗程7～14d。结果:治疗组在退热时间、咳嗽好转时间、音消失时间和平均治愈时间均较对照组短,局部疼痛、胃肠道不良反应及肝功能损伤程度明显低于对照组,差异均有统计学意义(P<0.05)。结论:阿奇霉素治疗小儿支原体肺炎的临床疗效优于红霉素,且耐受性好,不良反应少,安全可靠,值得临床推广应用。

Objective：To study the efficacy and safety of azithromycin aspartate in the treatment of mycoplasma pneumonia in children. methods： Eighty-four children with mycoplasma pneumonia were divided randomly into treatment group and control group , with 42 cases per group .The treatment group was treated with azithromycine aspartate 10mg/（kg·d）intravenous injection for 5 to 7 days and the control group was treated with erythromycin 20mg/（kg· d） intravenous injection for 7 to 14 days. Results： The pyretolysis time, cough improvement time, rale disappearing time and the mean time of healing well of treatment group were shorter than that of control group . The local ache , stomach and intestinal tract adverse reaction , and damage of hepatic function were less than those in control group. The difference was remarkable （ P 〈 0.05）. Condusion： Azithromycin aspartate is more effective and safer in treatment of mycoplasma pneumonia in children than erythromycin. It deserves to be applied in the clinic.